This is Why Investors are Pushing Into Psychedelics

May 9, 2021, By smallcapfirm,

Psychedelics have gone mainstream.

For one researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post.  Two, there’s rapidly changing consumer attitudes towards psychedelics, just as we saw with cannabis around the world. Three, with plenty of clinical trials supporting psychedelic treatments, it’s only a matter of time before big pharmaceutical companies begin to invest heavily, and incorporate psychedelics into their own drug pipelines.

Even more impressive, psilocybin has been found to help treat mental health issues, such as depression, anxiety, obsessive-compulsive disorder, and PTSD.  It may even be useful in treating obesity. LSD may be able to help patients with anxiety disorders and other medical issues.  MDMA-assisted therapy could help treat eating disorders, including anorexia and binge eating. Again, it’s only a matter of time before pharmaceutical companies jump at the opportunity, especially if psychedelics continue to show progress with mental health issues.

Leave a Reply

Your email address will not be published. Required fields are marked *